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Abstract: Pericardial mesothelioma remains a disease with a bleak
prognosis. We report the case of a patient with metastases to liver
and good response to pemetrexed and carboplatin-based combina-
tion chemotherapy and consequent prolonged progression-free
survival.
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BACKGROUND
Pericardial mesothelioma is a rare tumor with devas-
tating consequences. Promising data of pemetrexed and plat-
inum combination usage emerged in phase III trials (in terms
of median survival, vis-a`-vis gemcitabine and platinum) in
pleural mesothelioma, despite an overall poor prognosis.1 An
anecdote of efficacy of the pemetrexed-platinum combination
in primary peritoneal mesothelioma also has been reported.2
CASE REPORT
A 45 year-old nondiabetic man presented to us in
December of 2005 with history of illness with the symptoms
of non-productive cough and breathlessness and treatment
thereof for the previous year. Before presenting to us, the
patient had been evaluated at another institute for the pre-
sumptive diagnosis of pulmonary tuberculosis and had re-
ceived anti-tuberculosis treatment for approximately 9
months. After the anti-tuberculosis therapy, the patient was
re-evaluated at a heart institute for the increasing severity of
symptoms. Two-dimensional echocardiography suggested a
pericardial mass. Cardiomegaly and bilateral pleural effu-
sions (right more than left) were documented on chest roent-
genogram. Computed tomographic scan of the chest revealed
pericardial mass. He underwent partial excision of the peri-
cardial mass at the same tertiary cardiac center. The his-
topathologic examination of the pericardial mass was confir-
matory of diffuse malignant pericardial mesothelioma.
The patient was referred to our center for further
treatment. Clinical examination revealed tachycardia and
tachypnea. There was no evidence of pulsus paradoxus or
cardiac tamponade. Occasional crackles in the chest and lack
of organomegaly or tenderness in the abdomen were docu-
mented. Cardiac echo-Doppler study did not reveal tampon-
ade. A monophasic (epithelial) malignant mesothelioma was
confirmed, and on immunohistochemistry, positivity for cal-
retinin, CK, and Vimentin and negativity for CD 15, CEA,
and TTF were demonstrated at this institute on review, and
special tests were run on the slides. Postoperative computed
tomographic scan of the chest and abdomen showed left
pleural effusion residual mass in the pericardial cavity with
pericardial effusion. We observed hypodense lesions of vari-
able shapes and sizes, consistent with metastases in both
lobes of the liver. The patient also had pleural effusion and
nodularity in the lungs. He was started on pemetrexed and
carboplatin-based chemotherapy in January 2006 for the
metastatic disease. He received second cycle of chemother-
apy 25 days after the first cycle. Approximately a month after
the second cycle, the patient was admitted with symptoms of
hyponatremia of Syndrome of Inappropriate AVP Secretion
(SIADH). He received third cycle thereafter, and re-evaluation at
the end of three cycles with chest and whole-abdomen computed
tomography showed good partial regression (World Health Or-
ganization criteria) in the pericardial mass and left pleural
effusion. The patient finished the sixth cycle of chemotherapy in
June 2006. There was further shrinkage of the tumor amounting
to very good partial response (PR) (Figures 1 and 2).
The patient was followed after chemotherapy, and was
in an acceptable-to-good state of health with stable disease on
last evaluation, approximately 26 months after symptom
development and 6 months after the conclusion of chemo-
therapy, when this report was being written.
DISCUSSION
Malignant pericardial mesothelioma is a very rare tu-
mor that accounts for 4% of all cardiac and pericardial tumors
and 1% of all mesothelioma cases in the clinic.
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Remote metastases from the primary pericardial me-
sothelioma are occasionally reported. The reported sites of
metastasis are: mediastinal nodes, pleura, lung, brain, and
liver. To date, two cases of pericardial mesothelioma metas-
tasizing to the liver have been previously reported.3,4
The prognosis of pericardial mesothelioma is abysmal.
Surgery remains the main treatment modality. Best support-
ive care alone and systemic chemotherapy with palliative
intent are accepted approaches for those who are not candi-
dates for surgery. The average life expectancy at diagnosis is
10 months and at 2-year survival is 14%.5
Gemcitabine-platinum, gemcitabine-platinum-vinorel-
bine, and vincristine-adriamycin-cyclophosphamide are some
combinations that have yielded good response rates.6,7 In-
spired by the promising action of pemetrexed and platinum
combination in pleural mesothelioma,1 we started the patient
on a combination regimen consisting of pemetrexed and
carboplatin and received an excellent PR with subsequent
ongoing progression-free survival of 12 months since the
commencement of chemotherapy.
CONCLUSION
We report the case of a patient of pericardial mesothe-
lioma metastatic to the liver who had a good response to
pemetrexed and carboplatin-based combination chemother-
apy, and consequent prolonged continuing survival at the
time of the dispatch of this report.
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FIGURE 1. Baseline computed tomographic scan of the
chest: pericardial mesothelioma, before chemotherapy.
FIGURE 2. Computed tomographic scan of the chest after
six cycles of chemotherapy with pemetrexed and carboplatin
showing good partial response (PR).
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